We are very proud to announce our latest collaboration in the field of Telemedicine.
Successfully the most innovative products from the most advanced company TYTOCARE are to be imported and distributed exclusively by the largest conglomerate in Turkey, KOÇ Holding and by it’s healthcare operators for the great benefit of the Turkish patients.
This collaboration is a great success managed by our company as well as more medical collaborations to come.
NANOSONO, www.nanosono.com, the world leader in anti-bacterial coating is now our partner in activities for the Turkish market and production of various products and solutions in Turkey.
Our innovative nano-particles coating technology transforms almost any medical device, fabric, filters or any type of surfaces into an antibacterial surface and can prevent biofilm. Such capability makes us safe, effective and long term antimicrobial protection provider within the healthcare industry.
Using our unique patented process and materials to achieve a long term antibacterial and antibiofilm properties, we have successfully achieved total kill of MARSA, KPC, E. Coli and other resistant bacteria – within minutes. Because the mode of operation is not based on leaching of the coating, we are able to achieve high antibacterial efficacy, over a long period of time.
NanoSono Ltd. (NSC Ltd.) is in the key position to offer a cost-effective solution to a soon-to-be standardized market. In the near future, medical devices, fabrics that are potentially infection causes will require to gain anti-bacterial capabilities to be allowed within patient environments. The most effective way to protect the patients’ and the staffs’ environment is by avoiding the infection in the first place, preferably by eradicating the bacteria from the devices and the equipment that comes in contact with the patients and the hospital stuff. In addition, we make sure the patients’ environment, such as operating rooms, is as sterile as possible, we are also focused on lowering the risk of infection by making “carrier” materials within the patients’ direct environment such as robes, linens etc. anti-bacterial.
Since the 90’s Israel started exploring the interesting field of Cannabis. It has located Israel at the highest level of revealings, using abilities, production experience, pharmaceutical products and brought hope and help to millions of patients whom never had any solution.
We believe this market is the future, will go over $300B turnover annualy by 2025, therefore have invested in top large scale company as well as involved in it’s expending.
Our experience in this cooperation brings over 20 years of R&D, actual growing of over 50,000 sqm since 2008, largest GMP Pharma facility of over 5000 sqm with over 25 clinical trials.